Eupraxia Pharmaceuticals (EPRX) Competitors $5.91 +0.04 (+0.68%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$5.86 -0.05 (-0.93%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. CRMD, KURA, PRME, OCS, MRVI, ORKA, AVXL, AVBP, VIR, and PVLAShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include CorMedix (CRMD), Kura Oncology (KURA), Prime Medicine (PRME), Oculis (OCS), Maravai LifeSciences (MRVI), Oruka Therapeutics (ORKA), Anavex Life Sciences (AVXL), ArriVent BioPharma (AVBP), Vir Biotechnology (VIR), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors CorMedix Kura Oncology Prime Medicine Oculis Maravai LifeSciences Oruka Therapeutics Anavex Life Sciences ArriVent BioPharma Vir Biotechnology Palvella Therapeutics Eupraxia Pharmaceuticals (NASDAQ:EPRX) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Is EPRX or CRMD more profitable? CorMedix has a net margin of 42.11% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 42.73% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -626.84% -118.31% CorMedix 42.11%42.73%34.19% Do insiders & institutionals believe in EPRX or CRMD? 34.2% of CorMedix shares are owned by institutional investors. 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend EPRX or CRMD? Eupraxia Pharmaceuticals currently has a consensus target price of $11.00, suggesting a potential upside of 86.13%. CorMedix has a consensus target price of $18.00, suggesting a potential upside of 69.65%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86CorMedix 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70 Does the media favor EPRX or CRMD? In the previous week, CorMedix had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 4 mentions for CorMedix and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.79 beat CorMedix's score of -0.16 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, EPRX or CRMD? CorMedix has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.95CorMedix$43.47M19.05-$17.93M$0.7514.15 Which has more risk and volatility, EPRX or CRMD? Eupraxia Pharmaceuticals has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. SummaryCorMedix beats Eupraxia Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.09M$3.37B$6.12B$10.45BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-6.9522.7785.3227.36Price / SalesN/A486.78603.66198.22Price / CashN/A46.7037.4661.86Price / BookN/A10.5512.566.81Net Income-$25.50M-$52.58M$3.32B$276.80M7 Day Performance-4.52%0.09%0.63%0.42%1 Month Performance10.88%15.61%10.55%7.86%1 Year Performance138.31%15.13%75.10%41.24% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.6351 of 5 stars$5.91+0.7%$11.00+86.1%+143.2%$211.09MN/A-6.9529CRMDCorMedix2.8557 of 5 stars$11.27+1.6%$18.00+59.7%+5.2%$879.74M$43.47M15.0330KURAKura Oncology4.0219 of 5 stars$10.08+6.9%$24.10+139.1%-43.5%$874.94M$53.88M-4.46130PRMEPrime Medicine3.2319 of 5 stars$6.45+9.9%$8.92+38.2%+69.0%$868.00M$4.96M-3.15234Gap UpHigh Trading VolumeOCSOculis2.9383 of 5 stars$19.87+4.2%$41.00+106.3%+48.3%$867.52M$780K-7.442Analyst RevisionMRVIMaravai LifeSciences3.3421 of 5 stars$3.33+0.6%$5.22+56.7%-59.3%$850.35M$259.18M-2.45610Analyst ForecastOptions VolumeORKAOruka Therapeutics3.0603 of 5 stars$22.61+9.9%$42.00+85.8%+0.3%$846.74MN/A-8.05N/AAnalyst ForecastAVXLAnavex Life Sciences3.7264 of 5 stars$9.85+0.7%$44.00+346.7%+67.5%$846.02MN/A-17.2840AVBPArriVent BioPharma1.8969 of 5 stars$20.82+7.8%$39.14+88.0%-27.6%$844.67MN/A-5.1840Analyst DowngradeVIRVir Biotechnology3.3657 of 5 stars$6.05+6.9%$17.30+186.0%-21.7%$840.47M$74.21M-1.51580News CoverageAnalyst ForecastInsider TradeHigh Trading VolumePVLAPalvella Therapeutics2.0489 of 5 stars$74.85+5.8%$73.50-1.8%N/A$827.84M$42.81M-6.19N/AHigh Trading Volume Related Companies and Tools Related Companies CorMedix Competitors Kura Oncology Competitors Prime Medicine Competitors Oculis Competitors Maravai LifeSciences Competitors Oruka Therapeutics Competitors Anavex Life Sciences Competitors ArriVent BioPharma Competitors Vir Biotechnology Competitors Palvella Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
